The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
 
Megan Othus
Consulting or Advisory Role - Merck
Other Relationship - Bristol-Myers Squibb; Celgene; Glycomimetics; Grifols
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix; XZOM
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EMD Serono; EOM Pharmaceuticals; Gaido; Iylon; Jackson Laboratory for Genomic Medicine; LabCorp; Lanauria Therapeutics; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Precirix; Prosperdtx; Quanta Therapeutics; Recordati; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Sysmex (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
 
Sandip Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Iovance Biotherapeutics (Inst); Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics; Takeda (Inst); Takeda (Inst)
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Foundation Medicine; Guardant Health; Immuneoncia; Lilly; Lunit; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; BMS; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
 
Sapna Patel
Honoraria - Cedars Sinai; Clinical Care Options; Clinical Education Alliance (Inst); Emory University; OncLive/MJH Life Sciences; Paradigm; University of Michigan; Vindico Medical Education (Inst)
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; IDEAYA Biosciences; immatics; IO Biotech; MSD; Novartis; Obsidian Therapeutics; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; Melanoma Research Alliance (MRA); Melanoma Research Foundation; MSD; SITC/ACCC; SWOG; TriSalus Life Sciences
 
Jeffrey Sosman
Honoraria - Apexigen; Aveo; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Iovance Biotherapeutics; Jazz Pharmaceuticals
Research Funding - Werewolf Pharma (Inst)
 
Alexandra Snyder Charen
Employment - Generate Biomedicines
Stock and Other Ownership Interests - Allogene Therapeutics; Generate Biomedicines; Merck
Research Funding - BMS Brazil
 
Naiyer Rizvi
Employment - Synthekine
 
Theresa LaVallee
Employment - Coherus BioSciences
Leadership - Coherus BioSciences
Stock and Other Ownership Interests - AstraZeneca; Coherus BioSciences
 
David Felquate
Employment - iTEOS Therapeutics
 
Elizabeth Burton
No Relationships to Disclose
 
Phillip Futreal
Stock and Other Ownership Interests - Scorpion Therapeutics
Consulting or Advisory Role - GenePlus; Lepidyne; Scorpion Therapeutics
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Georgimmune (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Harriet Kluger
Consulting or Advisory Role - Bristol-Myers Squibb; ChemoCentryx; Clinigen Group; Eisai; GI Reviewers; Gigagen; Invox; Iovance Biotherapeutics; Merck; Pliant; Seranova Bio; Signatera; Werewolf Pharma
Speakers' Bureau - Merck
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)